Summit Therapeutics Provides Notice of Full Year Financial Results

Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its full year financial results for the year ended 31 January 2015 on Wednesday 6 May 2015.

Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the full year results press release, and a replay of the call will also be available through the Company's website, www.summitplc.com.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics)
Glyn Edwards / Richard Pye (UK office	Tel: [phone]
Erik Ostrowski (US office)	[phone]
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson	Tel: [phone]
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer	Tel: [phone]
MacDougall Biomedical Communications
(US media contact)	Tel: [phone]
Michelle Avery	[e-mail]
Peckwater PR
(Financial public relations, UK)	Tel: [phone]
Tarquin Edwards	[e-mail]